Why Biogen Stock Rose 14.7% in February

Shares of Biogen (NASDAQ: BIIB) rose 14.7% in February, according to data provided by S&P Global Market Intelligence, after the company won a patent ruling concerning its blockbuster multiple sclerosis drug.

In a case brought by generic-drug maker Mylan (NASDAQ: MYL), the U.S. Patent and Trademark Office's patent trial and appeal board ruled in Biogen's favor. That means Biogen's Tecfidera won't face competition until patent expiration in 2028 -- unless a Mylan appeal or other separate patent challenges result in a different decision.

Image source: Getty Images.

Continue reading

Source Fool.com